XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 29, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 7,073 $ 8,077
Short-term investments 1,750 3
Accounts receivable, less allowances of $202 and $193 7,943 8,221
Inventories 5,198 5,088
Contract assets, net 1,487 1,443
Other current assets 2,025 1,757
Total current assets 25,476 24,589
Property, plant and equipment, net 9,282 9,448
Acquisition-related intangible assets, net 15,519 16,670
Other assets 4,377 3,999
Goodwill 43,843 44,020
Total assets 98,496 98,726
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 5,121 3,609
Accounts payable 2,547 2,872
Accrued payroll and employee benefits 1,495 1,596
Contract liabilities 2,591 2,689
Other accrued expenses 3,019 3,246
Total current liabilities 14,772 14,012
Deferred income taxes 1,516 1,922
Other long-term liabilities 4,391 4,642
Long-term obligations 30,284 31,308
Redeemable noncontrolling interest 115 118
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued 0 0
Common stock, $1 par value, 1,200,000,000 shares authorized; 443,105,658 and 442,188,634 shares issued 443 442
Capital in excess of par value 17,649 17,286
Retained earnings 49,940 47,364
Treasury stock at cost, 61,110,092 and 55,541,290 shares (18,187) (15,133)
Accumulated other comprehensive income/(loss) (2,413) (3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity 47,432 46,735
Noncontrolling interests (12) (11)
Total equity 47,419 46,724
Total liabilities, redeemable noncontrolling interest and equity $ 98,496 $ 98,726